MRC2
MRC2 (mannose receptor C-type 2, also known as Endo180, CD280, CLEC13E and KIAA0709) is a membrane lectin receptor of the mannose receptor family. It internalises glycosylated ligands, including collagen, and contributes to extracellular matrix remodelling. Browse Assay Genie's current range of MRC2 research reagents below, or read on for the biology behind the target.
MRC2, the C-type mannose receptor 2, is thought to act as an endocytic lectin receptor with calcium-dependent lectin activity. It takes up glycosylated ligands from the extracellular space and releases them in an endosomal compartment through clathrin-mediated endocytosis. It may also take part in the plasminogen activation system, helping to control extracellular levels of PLAUR and PLAU, and so may regulate protease activity at the cell surface.
The MRC2 gene encodes a member of the mannose receptor family. Proteins in this family contain a fibronectin type II domain and multiple C-type lectin-like domains. The MRC2 protein mediates the internalisation and lysosomal degradation of collagen ligands, and it may contribute to the uptake, remodelling and degradation of extracellular collagen matrices. It may work together with the matrix metalloproteinases (MMPs) in extracellular matrix remodelling. Mouse and rat both have an Mrc2 ortholog.
The gene has several names. HGNC records the previous name "mannose receptor, C type 2", and the aliases include KIAA0709, ENDO180, CLEC13E and CD280. HGNC places it in both the CD molecules group and the C-type lectin domain containing group. Because of its role in collagen turnover, MRC2 may be involved in cancer progression and in other chronic tissue-destructive diseases. Its expression may play a role in the tumorigenesis and metastasis of several malignancies, including breast cancer, gliomas and metastatic bone disease.
MRC2 mediates internalisation and lysosomal degradation of collagen ligands, and may cooperate with matrix metalloproteinases in remodelling the extracellular matrix.
The receptor internalises glycosylated ligands by clathrin-mediated endocytosis and releases them in an endosomal compartment, making it a model for lectin-driven uptake.
MRC2 expression may play a role in tumorigenesis and metastasis of malignancies including breast cancer, gliomas and metastatic bone disease.
MRC2 may be involved in the plasminogen activation system, controlling extracellular PLAUR and PLAU levels and thereby regulating protease activity at the cell surface.
MRC2 is thought to be an endocytic lectin receptor with calcium-dependent lectin activity. It internalises glycosylated ligands, including collagen, by clathrin-mediated endocytosis and delivers them to endosomes and lysosomes. This supports extracellular matrix remodelling, possibly alongside matrix metalloproteinases.
MRC2 is also called Endo180, CD280, CLEC13E and KIAA0709. The HGNC full name is mannose receptor C-type 2, and the previous name was mannose receptor, C type 2. UniProt lists the protein as C-type mannose receptor 2. Check the datasheet of any product for its validated reactivity.
The NCBI Gene summary says MRC2 expression may play a role in tumorigenesis and metastasis of several malignancies, including breast cancer, gliomas and metastatic bone disease. UniProt adds that it may act on collagen turnover in other chronic tissue-destructive diseases. Mouse and rat have Mrc2 orthologs.
Other mannose receptor family members, C-type lectins, matrix metalloproteinases and plasminogen activation system proteins.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q9UBG0; product specifications from Assay Genie datasheets.